[ad_1]
Volunteers participating in the Pfizer / BioNTech COVID-19 vaccine trials who received a placebo will be able to receive a first dose of the vaccine by March 1, according to reports on Saturday.
The companies said the trial’s vaccine transition option means all participants can find out if they received the placebo. Participants who learn they have received the placebo “have the option of receiving the experimental vaccine while remaining in the study,” according to a statement from the trial participants.
US Food and Drug Administration officials and outside advisers, however, said Pfizer’s “blindfold” plan could make it harder to continue collecting safety and efficacy data. necessary for full vaccine approval by the FDA.
Trial participants who received the placebo will have two doses of the investigational vaccine reserved as part of the study, the companies said.
“The study doctor will follow the latest guidelines from the United States Centers for Disease Control and Prevention and their local health authorities to offer the vaccine transition option to participants on a priority basis,” the companies said, reported Reuters.
[ad_2]
Source link